摘要
45只SD大鼠分为正常对照组、糖尿病对照组、糖尿病罗格列酮治疗组,实验12周末以免疫组织化学和RT-PCR检测肾脏色素上皮衍生因子(PEDF)、基质金属蛋白酶2(MMP-2)和转化生长因子β1(TGF-β1)的表达.结果 显示,罗格列酮治疗可降低糖尿病大鼠增高的肾脏重量/体重比值、肌酐、尿素氮、尿蛋白排泄率、甘油三酯水平(均P<0.01).罗格列酮增加糖尿病大鼠肾脏降低的PEDF、MMP-2蛋白表达,降低升高的TGF-β1蛋白表达(均P<0.01).PEDF mRNA的表达也呈相似趋势.提示罗格列酮可通过调节肾脏PEDF、MMP-2及TGF-β1的表达对肾脏起到保护作用.
Forty-five male SD rats were divided into normal group, diabetic control group, and rosiglitazone treatment diabetic group.By the end of 12 weeks, the expressions of pigment epithelium-derived factor(PEDF), matrix metalloproteinase-2 (MMP-2), and transforming growth factor-β1 (TGF-β1) in the kidney were determined by immunohistochemistry and RT-PCR.The results showed that rosiglitazone decreased the increased kidney weight/body weight ratio, serum creatinine, blood ureanitrogen, urinary albumin excretion, triglyceride levels in diabetic rats (all P〈0.01).Rosiglitazone prevented the decreasing of protein expressions of PEDF and MMP-2 and the increasing of protein expression of TGF-β1 (all P〈0.01).PEDF mRNA showed a similar change,suggesting that renoprotection of rosiglitazone on diabetic rats may be mediated through regulating the expressions of PEDF, MMP-2, and TGF-β1.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2011年第1期66-69,共4页
Chinese Journal of Endocrinology and Metabolism
关键词
糖尿病肾病
色素上皮衍生因子
基质金属蛋白酶2
转化生长因子Β1
罗格列酮
Diabetic nephropathies
Pigment epithelium-derived factor
Matrix-metalloproteinase-2
Transforming growth factor-β1
Rosiglitazone